Nycomed Amersham chooses Nasdaq for APBiotech listing

Nycomed Amersham has become the latest European biotech company to opt for a secondary listing on Nasdaq in the US.

Nycomed Amersham, a UK company which is already listed on the London Stock Exchange (LSE), said that it had filed with the US Securities & Exchange Commission to float APBiotech, its drug discovery unit, on the US market.

WSJ Logo
The Worst Performer in Billionaires’ Portfolios? Trophy Art.External link

The Worst Performer in Billionaires’ Portfolios? Trophy Art.